Top

Published in:

01-11-2015 | Original Article

Immunoexpression of metalloproteinase 14 and tissue inhibitor of metalloproteinase 2 in colorectal carcinomas and lymph node metastases

Authors: Francisco Nélson Nóbrega Furtado, João Paulo Aguiar Sampaio, João Tarcisio Alves Maia-Filho, Renato Braga Vieira, Roberto César Pereira Lima-Júnior, Ronaldo Albuquerque Ribeiro, Paulo Roberto Carvalho Almeida

Published in: Comparative Clinical Pathology | Issue 6/2015

Abstract

Changes in metalloproteinase (MMP) and tissue inhibitor of metalloproteinases (TIMP) have been associated with tumor progression in colorectal cancer. However, the role of MMP-14 and TIMP-2 has yet to be determined. We investigated the differential expression of MMP-14 and TIMP-2 in colorectal carcinomas of the left and the right colon, as well as in mononuclear cells in primary tumors and their lymph node metastases. We performed an immunohistochemistry analysis of tumor samples obtained from 50 cases of colorectal cancer. We found that MMP-14 staining was positive in 100 % of cases, in contrast to normal mucosa (86 % positivity, P = 0.0451). Additionally, neoplastic cells showed a higher frequency of TIMP-2-positive staining (70 % versus 14 % of normal mucosa, P = 0.0004). Furthermore, MMP-14 expression in primary tumor-associated mononuclear cells was higher in cases without lymph node metastases (N0) in comparison to more advanced carcinomas (N1–N3) (P = 0.0353). MMP-14 and TIMP-2 expression was observed in neoplastic cells in primary tumors, with a higher frequency of increased expression of MMP-14 (82 %) than increased expression of TIMP-2 (22 %, P < 0.0001). The expression of MMP-14 and TIMP-2 was evaluated in each cell type and at each site, and the frequency of TIMP-2 expression in colonic lesions and in the lymph nodes was significantly higher than in tumor-infiltrating mononuclear cells (P = 0.0003 and P = 0.0406, respectively). Expression of MMP-14 and TIMP-2 in primary colorectal carcinomas and in their lymph node metastases suggests the involvement of these proteins in local invasion and tumor progression.

Al-Raawi D, Abu-El-Zahab H, El-Shinawi M, Mohamed MM (2011) Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer. Int J Clin Exp Med 4(4):265–275PubMedCentralPubMed

Altadill A, Eiro N, Gonzalez LO et al (2012) Comparative analysis of the expression of metalloproteases and their inhibitors in resected Crohn’s disease and complicated diverticular disease. Inflamm Bowel Dis 18(1):120–130CrossRefPubMed

Asano T, Tada M, Cheng S et al (2008) Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res 146(1):32–42CrossRefPubMed

Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115(Pt 19):3719–3727CrossRefPubMed

Benedix F, Meyer F, Kube R et al (2010) Right- and left-sided colonic cancer—different tumour entities. Zentralbl Chir 135(4):312–317CrossRefPubMed

Bernardo MM, Fridman R (2003) TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 374(Pt 3):739–745PubMedCentralCrossRefPubMed

Bonfil RD, Dong Z, Trindade Filho JC et al (2007) Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170(6):2100–2111PubMedCentralCrossRefPubMed

Buskens CJ, Sivula A, van Rees BP et al (2003) Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 52(12):1678–1683PubMedCentralCrossRefPubMed

Dong B, Sato M, Sakurada A et al (2005) Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: they correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation. J Thorac Cardiovasc Surg 130(3):733–739CrossRefPubMed

Felin C, Rocha A, Felin I, Grivicich I (2008) Expressão das metaloproteinases 2 e 9 em adenocarcinoma colorretal. Rev Amrigs 52(4):91–297

García MF, González-Reyes S, González LO et al (2010) Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol 91(4):324–334PubMedCentralCrossRefPubMed

Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation, and biological functions. Eur J Cell Biol 74(2):111–122PubMed

Groblewska M, Mroczko B, Gryko M et al (2014) Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumour Biol 35(4):3793–3802PubMedCentralCrossRefPubMed

Gurgel DC, Dornelas CA, Lima-Júnior RC et al (2012) An adapted tissue microarray for the development of a matrix arrangement of tissue samples. Pathol Res Pract 208(3):167–168CrossRefPubMed

Hadler-Olsen E, Fadnes B, Sylte I et al (2011) Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278(1):28–45CrossRefPubMed

Hong SW, Kang YK, Lee B et al (2011) Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 27(3):133–139PubMedCentralCrossRefPubMed

Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252PubMedCentralCrossRefPubMed

Kahlert C, Pecqueux M, Halama N et al (2014) Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. Br J Cancer 110(2):441–449PubMedCentralCrossRefPubMed

Kanazawa A, Oshima T, Yoshihara K et al (2010) Relation of MT1-MMP gene expression to outcomes in colorectal cancer. J Surg Oncol 102(6):571–575CrossRefPubMed

Kikuchi R, Noguchi T, Takeno S et al (2000) Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 83(2):215–218PubMedCentralCrossRefPubMed

Kim TD, Song KS, Li G et al (2006) Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6:211PubMedCentralCrossRefPubMed

Lafleur MA, Forsyth PA, Atkinson SJ et al (2001) Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. Biochem Biophys Res Commun 282(2):463–473CrossRefPubMed

Mbeunkui F, Johann DJ Jr (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63(4):571–582PubMedCentralCrossRefPubMed

Mclean MH, Murray GI, Stewart KN et al (2011) The inflammatory microenvironment in colorectal neoplasia. PLoS One 6(1):e15366PubMedCentralCrossRefPubMed

Meneses-García A, Betancourt AM, Abarca JH et al (2008) Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, TIMP-1 and TIMP-2 in angiocentric midfacial lymphomas. World J Surg Oncol 6:114PubMedCentralCrossRefPubMed

Murphy G, Nagase H (2008) Progress in matrix metalloproteinase research. Mol Aspects Med 29(5):290–308PubMedCentralCrossRefPubMed

Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002) Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52(4):255–264CrossRefPubMed

Ornstein DL, Cohn KH (2002) Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium. Dig Dis Sci 47(8):1821–1830CrossRefPubMed

Park KS, Kim SJ, Kim KH, Kim JC (2011) Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 26(2):391–397CrossRefPubMed

Pellikainen JM, Ropponen KM, Kataja VV et al (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10(22):7621–7628CrossRefPubMed

Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26(8):587–596PubMedCentralCrossRefPubMed

Sampaio JP, Cavalcante JR, Furtado FN et al (2014) A handcrafted tissue microarray for a matrix arrangement of tissue samples. J Pharmacol Toxicol Methods 70(1):70–72CrossRefPubMed

Sato H, Takino T (2010) Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci 101(4):843–847CrossRefPubMed

Schwandner O, Schlamp A, Broll R, Bruch HP (2007) Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 22(2):127–136CrossRefPubMed

Strongin AY (2010) Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 1803(1):133–141PubMedCentralCrossRefPubMed

Sugai T, Habano W, Jiao YF et al (2006) Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 8(2):193–201PubMedCentralCrossRefPubMed

Têtu B, Brisson J, Wang CS et al (2006) The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 8(3):R28PubMedCentralCrossRefPubMed

Trudel D, Fradet Y, Meyer F et al (2008) Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39(5):731–739CrossRefPubMed

Webster NL, Crowe SM (2006) Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 80(5):1052–1066CrossRefPubMed

Zagouri F, Sergentanis TN, Kalogera E et al (2011) Serum MMPs and TIMPs: may be predictors of breast carcinogenesis? Clin Chim Acta 412(7–8):537–540CrossRefPubMed

Title: Immunoexpression of metalloproteinase 14 and tissue inhibitor of metalloproteinase 2 in colorectal carcinomas and lymph node metastases
Authors: Francisco Nélson Nóbrega Furtado
João Paulo Aguiar Sampaio
João Tarcisio Alves Maia-Filho
Renato Braga Vieira
Roberto César Pereira Lima-Júnior
Ronaldo Albuquerque Ribeiro
Paulo Roberto Carvalho Almeida
Publication date: 01-11-2015
Publisher: Springer London
Published in: Comparative Clinical Pathology / Issue 6/2015
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-015-2085-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunoexpression of metalloproteinase 14 and tissue inhibitor of metalloproteinase 2 in colorectal carcinomas and lymph node metastases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Effects of diazinon on some immunological components of common carp, Cyprinus carpio juveniles

The influence of carob powder on lipid profile and histopathology of some organs in rats

Antioxidant, hypolipidemic, and anti-angiotensin-1-converting enzyme properties of lemon (Citrus limon) and lime (Citrus aurantifolia) juices

Effects of synbiotic (Biomin IMBO) on haematological and immunological components of Russian sturgeon, Acipenser guldenstadti

A hematologic and biochemical profile on 3-month-old hatchlings of Lepidochelys olivacea

Antioxidant and antidiabetic effects of gallic and protocatechuic acids: a structure–function perspective